Correlation Between Inhibikase Therapeutics and NGM Biopharmaceutica

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and NGM Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and NGM Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and NGM Biopharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and NGM Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of NGM Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and NGM Biopharmaceutica.

Diversification Opportunities for Inhibikase Therapeutics and NGM Biopharmaceutica

-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Inhibikase and NGM is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and NGM Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NGM Biopharmaceuticals and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with NGM Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NGM Biopharmaceuticals has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and NGM Biopharmaceutica go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and NGM Biopharmaceutica

If you would invest  228.00  in Inhibikase Therapeutics on September 12, 2024 and sell it today you would earn a total of  92.00  from holding Inhibikase Therapeutics or generate 40.35% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy0.3%
ValuesDaily Returns

Inhibikase Therapeutics  vs.  NGM Biopharmaceuticals

 Performance 
       Timeline  
Inhibikase Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
NGM Biopharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NGM Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, NGM Biopharmaceutica is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Inhibikase Therapeutics and NGM Biopharmaceutica Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibikase Therapeutics and NGM Biopharmaceutica

The main advantage of trading using opposite Inhibikase Therapeutics and NGM Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, NGM Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NGM Biopharmaceutica will offset losses from the drop in NGM Biopharmaceutica's long position.
The idea behind Inhibikase Therapeutics and NGM Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges